Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney

Ageing Research Reviews

Volumn 14, Issue 1, 2014, Pages 1-18

  Speeckaert, Marijn M ^a   Vanfraechem, Céline ^a   Speeckaert, Reinhart ^a   Delanghe, Joris R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Aging; Kidney; Peroxisome proliferator activated receptor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

AGING; CARDIOVASCULAR SYSTEM; DIABETIC NEPHROPATHY; DISEASE COURSE; EXPERIMENTAL STUDY; GERIATRIC DISORDER; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HUMAN; KIDNEY; KIDNEY CYST; KIDNEY DISEASE; KIDNEY FIBROSIS; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; NUTRIENT; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; METABOLISM;

AGING; ANIMALS; HUMANS; KIDNEY; KIDNEY DISEASES; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SIGNAL TRANSDUCTION;

EID: 84897045257     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.01.006     Document Type: Review

References (203)

1. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C., Cushman W.C., Simons-Morton D.G., Byington R.P. Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine 2010, 362:1563-1574.
2. Agarwal R., Saha C., Battiwala M., Vasavada N., Curley T., Chase S.D., Sachs N., Semret M.H. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney International 2005, 68:285-292.
3. Aljabri K., Kozak S.E., Thompson D.M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. American Journal of Medicine 2004, 116:230-235.
4. Al-Shali K.Z., House A.A., Hanley A.J., Khan H.M., Harris S.B., Zinman B., Mamakeesick M., Fenster A., Spence J.D., Hegele R.A. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 2004, 35:2036-2040.
5. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., Steiner G., DAIS Investigators Fenofibrate reduces progression to micro-albuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). American Journal of Kidney Diseases 2005, 45:485-493.
6. Ansquer J.C., Dalton R.N., Caussé E., Crimet D., Le Malicot K., Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. American Journal of Kidney Diseases 2008, 51:904-913.
7. Bae E.H., Kim I.J., Ma S.K., Kim S.W. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertension Research 2010, 33:255-262.
8. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension 2003, 17:7-12.
9. Bakris G.L., Ruilope L.M., McMorn S.O., Weston W.M., Heise M.A., Freed M.I., Porter L.E. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension 2006, 24:2047-2055.
10. Balakumar P., Kadian S., Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?. Pharmacological Research 2012, 65:430-436.
11. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
12. Barzilai N., Huffman D.M., Muzumdar R.H., Bartke A. The critical role of metabolic pathways in aging. Diabetes 2012, 6:1315-1322.
13. Blanchard P.G., Festuccia W.T., Houde V.P., St-Pierre P., BrÛlé S., Turcotte V., Côté M., Bellmann K., Marette A., Deshaies Y. Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion. Journal of Lipid Research 2012, 53:1117-1125.
14. Blazer-Yost B.L., Haydon J., Eggleston-Gulyas T., Chen J.H., Wang X., Gattone V., Torres V.E. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Research 2010, 2010:274376.
15. Berger J., Moller D.E. The mechanisms of action of PPARs. Annual Review of Medicine 2002, 53:409-435.
16. Bhalodia Y., Sheth N., Vaghasiya J., Jivani N. Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury. Renal Failure 2010, 32:1088-1094.
17. Bowling C.B., Muntner P. Epidemiology of chronic kidney disease among older adults: a focus on the oldest old. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2012, 67:1379-1386.
18. Brunelli S.M., Thadhani R., Ikizler T.A., Feldman H.I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney International 2009, 75:961-968.
19. Bruce R., Daniels A., Cundy T. Renal function changes in diabetic nephropathy induced by bezafibrate. Nephron 1996, 73:490.
20. Cabezas F., Lagos J., Céspedes C., Vio C.P., Bronfman M., Marzolo M.P. Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor-alpha and -gamma: implications for PPARs' roles in renal function. PLoS ONE 2011, 6:e16794.
21. Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A., Allen T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006, 49:766-774.
22. Cesari M., Vellas B., Gambassi G. The stress of aging. Experimental Gerontology 2013, 48:451-456.
23. Chafin C., Muse S., Hontecillas R., Bassaganya-Riera J., Caudell D.L., Shimp S.K., Rylander M.N., Zhang J., Li L., Reilly C.M. Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. Journal of Inflammation Research 2010, 3:127-134.
24. Chen H.H., Chen T.W., Lin H. Prostacyclin-induced peroxisome proliferator-activated receptor-alpha translocation attenuates NF-kappaB and TNF-alpha activation after renal ischemia-reperfusion injury. American Journal of Physiology. Renal Physiology 2009, 297:F1109-F1118.
25. Chen Y., Luo Q., Xiong Z., Liang W., Chen L., Xiong Z. Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells. International Journal of Clinical and Experimental Pathology 2012, 5:522-529.
26. Cheng C.F., Lian W.S., Chen S.H., Lai P.F., Li H.F., Lan Y.F., Cheng W.T., Lin H. Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARα-heme oxygenase-1 signaling pathway. Journal of Cellular Physiology 2012, 227:239-249.
27. Choudhury D., Levi M. Kidney aging-inevitable or preventable?. Nature Reviews Nephrology 2011, 7:706-717.
28. Chung B.H., Li C., Sun B.K., Lim S.W., Ahn K.O., Yang J.H., Choi Y.H., Yoon K.H., Sugawara A., Ito S., Kim J., Yang C.W. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. American Journal of Transplantation 2005, 5:1856-1867.
29. Chung S., Park C.W. Role of peroxisome proliferator-activated receptor α in diabetic nephropathy. Diabetes & Metabolism Journal 2011, 35:327-336.
30. Collino M., Benetti E., Miglio G., Castiglia S., Rosa A.C., Aragno M., Thiemermann C., Fantozzi R. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radical Biology & Medicine 2011, 50:345-353.
31. Cooper M.E., Jandeleit-Dahm K., Thomas M.C. Targets to retard the progression of diabetic nephropathy. Kidney International 2005, 68:1439-1445.
32. Dai B., Liu Y., Mei C., Fu L., Xiong X., Zhang Y., Shen X., Hua Z. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clinical Science (London) 2010, 119:323-333.
33. Davidson J.A., McMorn S.O., Waterhouse B.R., Cobitz A.R. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clinical Therapeutics 2007, 29:1900-1914.
34. Davis T.M., Ting R., Best J.D., Donoghoe M.W., Drury P.L., Sullivan D.R., Jenkins A.J., O'Connell R.L., Whiting M.J., Glasziou P.P., Simes R.J., Kesäniemi Y.A., Gebski V.J., Scott R.S., Keech A.C. Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290.
35. Deng Y.L., Xiong X.Z., Cheng N.S. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists. Hepatobiliary & Pancreatic Diseases International 2012, 11:467-478.
36. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Korányi L., Laakso M., Mokán M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J., PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
37. DREAM Trial Investigators, Dagenais G.R., Gerstein H.C., Holman R., Budaj A., Escalante A., Hedner T., Keltai M., Lonn E., McFarlane S., McQueen M., Teo K., Sheridan P., Bosch J., Pogue J., Yusuf S. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008, 31:1007-1014.
38. Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Chamaillard M., Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55:1341-1349.
39. Fedorova L.V., Sodhi K., Gatto-Weis C., Puri N., Hinds T.D., Shapiro J.I., Malhotra D. Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE 2013, 8:e64436.
40. Forsblom C., Hiukka A., Leinonen E.S., Sundvall J., Groop P.H., Taskinen M.R. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010, 33:215-220.
41. Giaginis C., Tsourouflis G., Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Current Molecular Medicine 2008, 8:562-579.
42. Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrology Dialysis Transplantation 2012, 27:2642-2649.
43. Gourtsoyiannis N., Prassopoulos P., Cavouras D., Pantelidis N. The thickness of the renal parenchyma decreases with age: a CT study of 360 patients. American Journal of Roentgenology 1990, 155:541-544.
44. Goya K., Sumitani S., Xu X., Kitamura T., Yamamoto H., Kurebayashi S., Saito H., Kouhara H., Kasayama S., Kawase I. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:658-663.
45. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circulation Research 1994, 74:1141-1148.
46. Guan Y., Zhang Y., Davis L., Breyer M.D. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. American Journal of Physiology 1997, 273:F1013-F1022.
47. Halimi J.M., Sautenet B., Gatault P., Roland M., Giraudeau B. Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus?. Fundamental & Clinical Pharmacology 2012, 26:771-782.
48. Hanefeld M., Brunetti P., Schernthaner G.H., Matthews D.R., Charbonnel B.H., QUARTET Study Group One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27:141-147.
49. Haraguchi K., Shimura H., Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proliferatoractivated receptor (PPAR) gamma activators. Clinical and Experimental Nephrology 2003, 7:27-32.
50. Hasegawa K., Wakino S., Yoshioka K., Tatematsu S., Hara Y., Minakuchi H., Sueyasu K., Washida N., Tokuyama H., Tzukerman M., Skorecki K., Hayashi K., Itoh H. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. Journal of Biological Chemistry 2010, 285:13045-13056.
51. Hashimoto K., Kamijo Y., Nakajima T., Harada M., Higuchi M., Ehara T., Shigematsu H., Aoyama T. PPARα activation protects against anti-Thy1 nephritis by suppressing glomerular NF-κB signaling. PPAR Research 2012, 2012:976089.
52. Hayashida S., Arimoto A., Kuramoto Y., Kozako T., Honda S., Shimeno H., Soeda S. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Molecular and Cellular Biochemistry 2010, 339:285-292.
53. Hietakangas V., Cohen S.M. Regulation of tissue growth through nutrient sensing. Annual Review of Genetics 2009, 43:389-410.
54. Higashihara E., Horie S., Muto S., Mochizuki T., Nishio S., Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clinical and Experimental Nephrology 2012, 16:622-628.
55. Howroyd P., Swanson C., Dunn C., Cattley R.C., Corton J.C. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicologic Pathology 2004, 32:591-599.
56. Hu M.C., Shi M., Zhang J., Quinones H., Griffith C., Kuro O., Moe O.W. Klotho deficiency causes vascular calcification in chronic kidney disease. Journal of the American Society of Nephrology 2011, 22:124-136.
57. Hung A.M., Roumie C.L., Greevy R.A., Liu X., Grijalva C.G., Murff H.J., Ikizler T.A., Griffin M.R. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney International 2012, 81:698-706.
58. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
59. Jin H.M., Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney and Blood Pressure Research 2007, 30:203-211.
60. Johnson E.F., Palmer C.N.A., Griffin K.J., Hsu M.H. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB Journal 1996, 10:1241-1248.
61. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
62. Jun M., Zhu B., Tonelli M., Jardine M.J., Patel A., Neal B., Liyanage T., Keech A., Cass A., Perkovic V. Effects of fibrates in kidney disease: a systematic review and meta-analysis. Journal of the American College of Cardiology 2012, 60:2061-2071.
63. Kadian S., Mahadevan N., Balakumar P. Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. European Journal of Pharmacology 2013, 698:388-396.
64. Kamijo Y., Hora K., Tanaka N., Usuda N., Kiyosawa K., Nakajima T., Gonzalez F.J., Aoyama T. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. Journal of the American Society of Nephrology 2002, 13:1691-1702.
65. Kamijo Y., Hora K., Kono K., Takahashi K., Higuchi M., Ehara T., Kiyosawa K., Shigematsu H., Gonzalez F.J., Aoyama T. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. American Society of Nephrology 2007, 18:3089-3100.
66. Kanaguchi Y., Suzuki Y., Osaki K., Sugaya T., Horikoshi S., Tomino Y. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. Nephrology Dialysis Transplantation 2011, 26:3465-3473.
67. Kanjanabuch T., Ma L.J., Chen J., Pozzi A., Guan Y., Mundel P., Fogo A.B. PPAR-gamma agonist protects podocytes from injury. Kidney International 2007, 71:1232-1239.
68. Kapil A., Singh J.P., Kaur T., Singh B., Singh A.P. Involvement of peroxisome proliferator-activated receptor gamma in vitamin D-mediated protection against acute kidney injury in rats. Journal of Surgical Research 2013, 185:774-783.
69. Katavetin P., Eiam-Ong S., Suwanwalaikorn S. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. Journal of the Medical Association of Thailand 2006, 89:170-177.
70. Kawai T., Masaki T., Doi S., Arakawa T., Yokoyama Y., Doi T., Kohno N., Yorioka N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Laboratory Investigation 2009, 89:47-58.
71. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators.
72. Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Pettersson S., Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclearcytoplasmic shuttling of PPAR-γ and RelA. Nature Immunology 2003, 5:104-112.
73. Ketsawatsomkron P., Pelham C.J., Groh S., Keen H.L., Faraci F.M., Sigmund C.D. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?. Journal of Biological Chemistry 2010, 285:9311-9316.
74. Khurana S., Chakraborty S., Lam M., Liu Y., Su Y.T., Zhao X., Saleem M.A., Mathieson P.W., Bruggeman L.A., Kao H.Y. Familial focal segmental glomerulosclerosis (FSGS)-linked α-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors. Journal of Biological Chemistry 2012, 287:12027-12035.
75. Kim J.Y., Kim D.H., Choi J., Park J.K., Jeong K.S., Leeuwenburgh C., Yu B.P., Chung H.Y. Changes in lipid distribution during aging and its modulation by calorie restriction. Age (Dordrecht, Netherlands) 2009, 31:127-142.
76. Kim H.J., Ham S.A., Kim M.Y., Hwang J.S., Lee H., Kang E.S., Yoo T., Woo I.S., Yabe-Nishimura C., Paek K.S., Kim J.H., Seo H.G. PPARδ coordinates angiotensin II-induced senescence in vascular smooth muscle cells through PTEN-mediated inhibition of superoxide generation. Journal of Biological Chemistry 2011, 286:44585-44593.
77. Kim D.H., Kim J.M., Lee E.K., Choi Y.J., Kim C.H., Choi J.S., Kim N.D., Yu B.P., Chung H.Y. Modulation of FoxO1 phosphorylation/acetylation by baicalin during aging. Journal of Nutritional Biochemistry 2012, 23:1277-1284.
78. Kincaid-Smith P., Fairley K.F., Farish S., Best J.D., Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008, 13:58-62.
79. Kitada M., Kume S., Takeda-Watanabe A., Kanasaki K., Koya D. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical Science (London) 2013, 124:153-164.
80. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:7355-7359.
81. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Song H.K., Han K.H., Kim H.K., Han J.Y., Cha D.R. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology Dialysis Transplantation 2008, 23:2750-2760.
82. Koch A., Völzke A., Wünsche C., Meyer zu Heringdorf D., Huwiler A., Pfeilschifter J. Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells. British Journal of Pharmacology 2012, 166:1018-1032.
83. König B., Koch A., Spielmann J., Hilgenfeld C., Stangl G.I., Eder K. Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochemical Pharmacology 2007, 73:574-585.
84. Kono K., Kamijo Y., Hora K., Takahashi K., Higuchi M., Kiyosawa K., Shigematsu H., Gonzalez F.J., Aoyama T. PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. American Journal of Physiology. Renal Physiology 2009, 296:F328-F336.
85. Kostapanos M.S., Florentin M., Elisaf M.S. Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation 2013, 43:522-531.
86. Kouroumichakis I., Papanas N., Zarogoulidis P., Liakopoulos V., Maltezos E., Mikhailidis D.P. Fibrates: therapeutic potential for diabetic nephropathy?. European Journal of Internal Medicine 2012, 23:309-316.
87. Koya D., Kitada M., Kume S., Kanasaki K. Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathy. Clinical and Experimental Nephrology 2013, 10.1007/s10157-013-0908-3.
88. Krönke G., Kadl A., Ikonomu E., Blüml S., Fürnkranz A., Sarembock I.J., Bochkov V.N., Exner M., Binder B.R., Leitinger N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1276-1282.
89. Krysiak R., Gdula-Dymek A., Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. American Journal of Cardiology 2011, 107. 1010.e1-1018.e1.
90. Kume S., Uzu T., Horiike K., Chin-Kanasaki M., Isshiki K., Araki S., Sugimoto T., Haneda M., Kashiwagi A., Koya D. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. Journal of Clinical Investigation 2010, 120:1043-1055.
91. Kume S., Thomas M.C., Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012, 61:23-29.
92. Kume S., Kitada M., Kanasaki K., Maegawa H., Koya D. Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy. Archives of Pharmacal Research 2013, 36:230-236.
93. Kusunoki H., Taniyama Y., Rakugi H., Morishita R. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptor-γ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. Journal of the American Heart Association 2013, 2:e000103.
94. Lachin J.M., Viberti G., Zinman B., Haffner S.M., Aftring R.P., Paul G., Kravitz B.G., Herman W.H., Holman R.R., Kahn S.E., ADOPT Study Group Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology 2011, 6:1032-1040.
95. Lai K.N., Chan L.Y., Guo H., Tang S.C., Leung J.C. Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy. Pediatric Nephrology 2011, 26:257-266.
96. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001, 86:280-288. Rosiglitazone Clinical Trials Study Group.
97. Lee Y.H., Lee N.H., Bhattarai G., Yun J.S., Kim T.I., Jhee E.C., Yi H.K. PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibroblast. Cell Biochemistry and Function 2010, 28:490-496.
98. Lee Y.J., Han H.J. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells. American Journal of Physiology. Renal Physiology 2010, 298:F1263-F1275.
99. Lee E.Y., Kim G.T., Hyun M., Kim S., Seok S., Choi R., Lee M.Y., Chung C.H. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrology Dialysis Transplantation 2012, 27:4069-4079.
100. Lee H., Ham S.A., Kim M.Y., Kim J.H., Paek K.S., Kang E.S., Kim H.J., Hwang J.S., Yoo T., Park C., Kim J.H., Lim D.S., Han C.W., Seo H.G. Activation of PPARδ counteracts angiotensin II-induced ROS generation by inhibiting rac1 translocation in vascular smooth muscle cells. Free Radical Research 2012, 46:912-919.
101. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., Baud L. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. Journal of the American Society of Nephrology 2005, 16:2395-2402.
102. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009, 150:604-612. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), (Erratum in 2011: Annals of Internal Medicine, 155, 408).
103. Levin A., Duncan L., Djurdjev O., Shapiro R.J., Frohlich J., Belanger A., Dumas R., Ross S. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clinical Nephrology 2000, 53:140-146.
104. Li S., Wu P., Yarlagadda P., Vadjunec N.M., Proia A.D., Harris R.A., Portilla D. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. American Journal of Physiology. Renal Physiology 2004, 286:F572-F580.
105. Li S., Nagothu K.K., Desai V., Lee T., Branham W., Moland C., Megyesi J.K., Crew M.D., Portilla D. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. Kidney International 2009, 76:1049-1062.
106. Li S., Mariappan N., Megyesi J., Shank B., Kannan K., Theus S., Price P.M., Duffield J.S., Portilla D. Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction. American Journal of Physiology. Renal Physiology 2013, 305:F618-F627.
107. Li R., Wang Y., Liu Y., Chen Q., Fu W., Wang H., Cai H., Peng W., Zhang X. Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells. PLoS ONE 2013, 8:e58848.
108. Liang Y.J., Jian J.H., Liu Y.C., Juang S.J., Shyu K.G., Lai L.P., Wang B.W., Leu J.G. Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. Diabetes/Metabolism Research and Reviews 2010, 26:406-416.
109. Lim J.H., Kim E.N., Kim M.Y., Chung S., Shin S.J., Kim H.W., Yang C.W., Kim Y.S., Chang Y.S., Park C.W., Choi B.S. Age-associated molecular changes in the kidney in aged mice. Oxidative Medicine and Cellular Longevity 2012, 2012:171383.
110. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Journal of the American Medical Association 2007, 298:1180-1188.
111. Liu Y., Dai B., Fu L., Jia J., Mei C. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic & Clinical Pharmacology & Toxicology 2010, 106:523-530.
112. Liu Y., Dai B., Xu C., Fu L., Hua Z., Mei C. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PLoS ONE 2011, 6:e28915.
113. Liu C., Zhang Y., Yuan L., Fu L., Mei C. Rosiglitazone inhibits insulin-like growth factor-1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Molecular Medicine Reports 2013, 8:861-864.
114. Ma L.J., Marcantoni C., Linton M.F., Fazio S., Fogo A.B. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney International 2001, 59:1899-1910.
115. Marion-Letellier R., Dechelotte P., Iacucci M., Ghosh S. Dietary modulation of peroxisome proliferator-activated receptor gamma. Gut 2009, 58:586-593.
116. Marx N., Mackman N., Schönbeck U., Yilmaz N., Hombach V., Libby P., Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103:213-219.
117. Matthews D.R., Charbonnel B.H., Hanefeld M., Brunetti P., Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews 2005, 21:167-174.
118. McLachlan M., Wasserman P. Changes in sizes and distensibility of the aging kidney. British Journal of Radiology 1981, 54:488-491.
119. Melk A., Schmidt B.M., Takeuchi O., Sawitzki B., Rayner D.C., Halloran P.F. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney International 2004, 65:510-520.
120. Min L.J., Mogi M., Iwai M., Horiuchi M. Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Research Reviews 2009, 8:113-121.
121. Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney International 2007, 72:1367-1373.
122. Modrick M.L., Kinzenbaw D.A., Chu Y., Sigmund C.D., Faraci F.M. Peroxisome proliferator-activated receptor-γ protects against vascular aging. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2012, 302:R1184-R1190.
123. Moreno M., Lombardi A., Silvestri E., Senese R., Cioffi F., Goglia F., Lanni A., de Lange P. PPARs: nuclear receptors controlled by, and controlling, nutrient handling through nuclear and cytosolic signaling. PPAR Research 2010, 435689.
124. Morgan C.L., Poole C.D., Evans M., Barnett A.H., Jenkins-Jones S., Currie C.J. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012, 97:4605-4612.
125. Morikawa A., Ishizeki K., Iwashima Y., Yokoyama H., Muto E., Oshima E., Sekiguchi M., Miura T., Itoh H., Haneda M. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. Clinical and Experimental Nephrology 2011, 15:848-853.
126. Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. Journal of Biological Chemistry 1997, 272:8071-8076.
127. Mukundan L., Odegaard J.I., Morel C.R., Heredia J.E., Mwangi J.W., Ricardo-Gonzalez R.R., Goh Y.P., Eagle A.R., Dunn S.E., Awakuni J.U., Nguyen K.D., Steinman L., Michie S.A., Chawla A. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nature Medicine 2009, 15:1266-1272.
128. Nagai T., Tomizawa T., Nakajima K., Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. Journal of Atherosclerosis and Thrombosis 2000, 7:91-96.
129. Nagao S., Yamaguchi T. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Current Molecular Pharmacology 2012, 5:292-300.
130. Nakamura T., Ushiyama C., Shimada N., Hayashi K., Ebihara I., Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes and its Complications 2000, 14:250-254.
131. Nakamura T., Ushiyama C., Osada S., Hara M., Shimada N., Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001, 50:1193-1196.
132. Nakamura T., Matsuda T., Kawagoe Y., Ogawa H., Takahashi Y., Sekizuka K., Koide H. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004, 53:1382-1386.
133. Nakamura T., Sugaya T., Kawagoe Y., Ueda Y., Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes/Metabolism Research and Reviews 2006, 22:385-389.
134. Ouali F., Djouadi F., Merlet-Bénichou C., Bastin J. Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney. American Journal of Physiology 1998, 275:F777-F784.
135. Perico N., Remuzzi G., Benigni A. Aging and the kidney. Current Opinion in Nephrology and Hypertension 2011, 20:312-317.
136. Petrica L., Vlad A., Petrica M., Jianu C.D., Gluhovschi G., Gadalean F., Dumitrascu V., Ianculescu C., Firescu C., Giju S., Gluhovschi C., Bob F., Velciov S., Bozdog G., Milas O., Marian R., Ursoniu S. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2011, 94:22-32.
137. Pistrosch F., Her brig K., Kindle B., Passover J., Fischer S., Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54:2206-2211.
138. Pistrosch F., Passover J., Her brig K., Schwanebeck U., Gross P., Bornstein S.R. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Hormone and Metabolic Research 2012, 44:914-918.
139. Rahman M., Halade G.V., Bhattacharya A., Fernandes G. The fat-1 transgene in mice increases antioxidant potential, reduces pro-inflammatory cytokine levels, and enhances PPAR-gamma and SIRT-1 expression on a calorie restricted diet. Oxidative Medicine and Cellular Longevity 2009, 2:307-316.
140. Ranganathan P.V., Jayakumar C., Ramesh G. Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. American Journal of Physiology. Renal Physiology 2013, 304:F948-F957.
141. Reel B., Guzeloglu M., Bagriyanik A., Atmaca S., Aykut K., Albayrak G., Hazan E. The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. Journal of Surgical Research 2013, 182:176-184.
142. Revelo M.P., Federspiel C., Helderman H., Fogo A.B. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrology Dialysis Transplantation 2005, 20:2812-2819.
143. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochimica et Biophysica Acta 2007, 1771:926-935.
144. Roszer T., Menéndez-Gutiérrez M.P., Lefterova M.I., Alameda D., Núñez V., Lazar M.A., Fischer T., Ricote M. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency. Journal of Immunology 2011, 186:621-631.
145. Ruan X., Zheng F., Guan Y. PPARs and the kidney in metabolic syndrome. American Journal of Physiology. Renal Physiology 2008, 294:F1032-F1047.
146. Saga D., Sakatsume M., Ogawa A., Tsubata Y., Kaneko Y., Kuroda T., Sato F., Ajiro J., Kondo D., Miida T., Narita I., Gejyo F. Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis. Kidney International 2005, 67:1821-1829.
147. Sakamoto A., Hongo M., Saito K., Nagai R., Ishizaka N. Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. European Journal of Pharmacology 2012, 682:131-136.
148. Samuelsson O., Attman P.O., Knight-Gibson C., Kron B., Larsson R., Mulec H., Weiss L., Alaupovic P. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 1997, 75:286-294.
149. Sarafidis P.A., Lasaridis A.N. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. American Journal of Hypertension 2006, 19:646-653.
150. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American Journal of Kidney Diseases 2010, 55:835-847.
151. Sato K., Sugawara A., Kudo M., Uruno A., Ito S., Takeuchi K. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertension Research 2004, 27:417-425.
152. Sauve A.A., Youn D.Y. Sirtuins: NAD(+)-dependent deacetylase mechanism and regulation. Current Opinion in Chemical Biology 2012, 16:535-543.
153. Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P., Quartet [corrected] Study Group Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology and Metabolism 2004, 89:6068-6076.
154. Schneider F., Vossler S., Franke S., Bär F., Conrad T. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. International Journal of Clinical Pharmacology and Therapeutics 2009, 47:311-320.
155. Sen U., Tyagi S.C. Homocysteine and hypertension in diabetes: does PPARgamma have a regulatory role?. PPAR Research 2010, 806538.
156. Setti G., Hayward A., Dessapt C., Barone F., Buckingham R., White K., Bilous R., Hiroshi K., Gruden G., Viberti G., Gnudi L. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. American Journal of Nephrology 2010, 32:393-402.
157. Shahidi S., Pakzad B., Mortazavi M., Akbari M., Seirafian S., Atapour A., Al Saeidi S., Shayegannejad A. Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease. Journal of Research in Medical Sciences 2011, 16:1459-1465.
158. Shin S.J., Lim J.H., Chung S., Youn D.Y., Chung H.W., Kim H.W., Lee J.H., Chang Y.S., Park C.W. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertension Research 2009, 32:835-845.
159. Singh J.P., Singh A.P., Bhatti R. Explicit role of peroxisome proliferator-activated receptor gamma in gallic acid-mediated protection against ischemia-reperfusion-induced acute kidney injury in rats. Journal of Surgical Research 2013, 10.1016/j.jss.2013.11.1088.
160. Sivarajah A., Chatterjee P.K., Patel N.S., Todorovic Z., Hattori Y., Brown P.A., Stewart K.N., Mota-Filipe H., Cuzzocrea S., Thiemermann C. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. American Journal of Nephrology 2003, 23:267-276.
161. Slinin Y., Ishani A., Rector T., Fitzgerald P., MacDonald R., Tacklind J., Rutks I., Wilt T.J. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. American Journal of Kidney Diseases 2012, 60:747-769.
162. Smulders Y.M., van Eeden A.E., Stehouwer C.D., Weijers R.N., Slaats E.H., Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. European Journal of Clinical Investigation 1997, 27:997-1002.
163. Song J., Sakatsume M., Narita I., Goto S., Omori K., Takada T., Saito N., Ueno M., Gejyo F. Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clinical Genetics 2003, 64:398-403.
164. Stenvinkel P., Larsson T.E. Chronic kidney disease: a clinical model of premature aging. American Journal of Kidney Diseases 2013, 62:339-351.
165. Sung B., Park S., Yu B.P., Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2004, 59:997-1006.
166. Sung B., Park S., Yu B.P., Chung H.Y. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Experimental Gerontology 2006, 41:590-599.
167. Tanaka Y., Kume S., Araki S., Isshiki K., Chin-Kanasaki M., Sakaguchi M., Sugimoto T., Koya D., Haneda M., Kashiwagi A., Maegawa H., Uzu T. Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney International 2011, 79:871-882.
168. Tang C., Pathare G., Michael D., Fajol A., Eichenmüller M., Lang F. Downregulation of Klotho expression by dehydration. American Journal of Physiology. Renal Physiology 2011, 301:F745-F750.
169. Ting R.D., Keech A.C., Drury P.L., Donoghoe M.W., Hedley J., Jenkins A.J., Davis T.M., Lehto S., Celermajer D., Simes R.J., Rajamani K., Stanton K., FIELD Study Investigators Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012, 35:218-225.
170. Toblli J.E., Ferrini M.G., Cao G., Vernet D., Angerosa M., Gonzalez-Cadavid N.F. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrology Dialysis Transplantation 2009, 24:2384-2391.
171. Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. American Journal of Kidney Disesases 2004, 44:832-839.
172. Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C., Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney International 2004, 66:1123-1130.
173. Tovar-Palacio C., Torres N., Diaz-Villaseñor A., Tovar A.R. The role of nuclear receptors in the kidney in obesity and metabolic syndrome. Genes & Nutrition 2012, 7:483-498.
174. Tracz M.J., Alam J., Nath K.A. Physiology and pathophysiology of heme: implications for kidney disease. American Society of Nephrology 2007, 18:414-420.
175. Tsuruoka S., Kai H., Usui J., Morito N., Saito C., Yoh K., Yamagata K. Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis. Internal Medicine 2013, 52:303-308.
176. Tzoulaki I., Molokhia M., Curcin V., Little M.P., Millett C.J., Ng A., Hughes R.I., Khunti K., Wilkins M.R., Majeed A., Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. British Medical Journal 2009, 339:b4731.
177. Venegas-Pont M., Sartori-Valinotti J.C., Maric C., Racusen L.C., Glover P.H., McLemore G.R., Jones A.V., Reckelhoff J.F., Ryan M.J. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2009, 296:R1282-R1289.
178. Wang Y., Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009, 54:810-817.
179. Wanner N., Hartleben B., Herbach N., Goedel M., Stickel N., Zeiser R., Walz G., Moeller M.J., Grahammer F., Huber T.B. Unraveling the role of podocyte turnover in glomerular aging and injury. Journal of the American Society of Nephrology 2014, 10.1681/ASN.2013050452.
180. Weinberg J.M. Mitochondrial biogenesis in kidney disease. Journal of the American Society of Nephrology 2011, 22:431-436.
181. Westerweel P.E., Verhaar M.C. Protective actions of PPAR-gamma activation in renal endothelium. PPAR Research 2008, 2008:635680.
182. Westerweel P.E., den Ouden K., Nguyen T.Q., Goldschmeding R., Joles J.A., Verhaar M.C. Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing. American Journal of Physiology. Renal Physiology 2008, 294:F379-F384.
183. Wilding J.P. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes, Obesity and Metabolism 2012, 14:973-982.
184. Wu Q.Q., Wang Y., Senitko M., Meyer C., Wigley W.C., Ferguson D.A., Grossman E., Chen J., Zhou X.J., Hartono J., Winterberg P., Chen B., Agarwal A., Lu C.Y. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. American Journal of Physiology. Renal Physiology 2011, 300:F1180-F1192.
185. Xiao J., Leung J.C., Chan L.Y., Tang S.C., Lai K.N. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clinical Immunology 2009, 132:266-276.
186. Xu X., Fan M., He X., Liu J., Qin J., Ye J. Aging aggravates long-term renal ischemia-reperfusion injury in a rat model. Journal of Surgical Research 2013, 10.1016/j.jss.2013.10.008.
187. Yanagawa T., Araki A., Sasamoto K., Shirabe S., Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004, 53:353-357.
188. Yang T., Michele D.E., Park J., Smart A.M., Lin Z., Brosius F.C., Schnermann J.B., Briggs J.P. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. American Journal of Physiology 1999, 277:F966-F973.
189. Yang H.C., Ma L.J., Ma J., Fogo A.B. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney International 2006, 69:1756-1764.
190. Yang H.C., Deleuze S., Zuo Y., Potthoff S.A., Ma L.J., Fogo A.B. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. Journal of the American Society of Nephrology 2009, 20:2380-2388.
191. Ye P., Wang Z.J., Zhang X.J., Zhao Y.L. Agerelated decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia. Chinese Medical Journal (English Edition) 2005, 118:1093-1098.
192. Ye P., Zhang X.J., Wang Z.J., Zhang C. Effect of aging on the expression of peroxisome proliferator-activated receptor gamma and the possible relation to insulin resistance. Gerontology 2006, 52:69-75.
193. Yoshihara D., Kurahashi H., Morita M., Kugita M., Hiki Y., Aukema H.M., Yamaguchi T., Calvet J.P., Wallace D.P., Nagao S. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. American Journal of Physiology. Renal Physiology 2011, 300:F465-F474.
194. Yuan Y., Zhang A., Huang S., Ding G., Chen R. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. American Journal of Physiology. Renal Physiology 2011, 300:F393-F402.
195. Zambrano S., Blanca A.J., Ruiz-Armenta M.V., Miguel-Carrasco J.L., Arévalo M., Mate A., Vázquez C.M. l-Carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. American Journal of Hypertension 2014, 10.1093/ajh/hpt268.
196. Zaza G., Bernich P., Lupo A., 'Triveneto' Register of Renal Biopsies (TVRRB) Incidence of primary glomerulonephritis in a large North-Eastern Italian area: a 13-year renal biopsy study. Nephrology Dialysis Transplantation 2013, 28:367-372.
197. Zhang H., Li Y.,Y., Wu J., Zhao B., Guan Y., Chien S., Wang N. Klotho is a target gene of PPAR-gamma. Kidney International 2008, 74:732-739.
198. Zhang R., Zheng F. PPAR-gamma and aging: one link through klotho?. Kidney International 2008, 74:702-704.
199. Zhang H., Zhu S., Chen J., Tang Y., Hu H., Mohan V., Venkatesan R., Wang J., Chen H. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012, 35:1388-1393.
200. Zhao Y.Y., Weir M.A., Manno M., Cordy P., Gomes T., Hackam D.G., Juurlink D.N., Mamdani M., Moist L., Parikh C.R., Paterson J.M., Wald R., Yao Z., Garg A.X. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Annals of Internal Medicine 2012, 156:560-569.
201. Zou R., Xu G., Liu X.C., Han M., Jiang J.J., Huang Q., He Y., Yao Y. PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis. Acta Pharmacologica Sinica 2010, 31:43-50.
202. Zuo Z., Lei H., Wang X., Wang Y., Sonntag W., Sun Z. Aging-related kidney damage is associated with a decrease in klotho expression and an increase in superoxide production. Age (Dordrecht, Netherlands) 2011, 33:261-274.
203. Zuo Y., Yang H.C., Potthoff S.A., Najafian B., Kon V., Ma L.J., Fogo A.B. Protective effects of PPARγ agonist in acute nephrotic syndrome. Nephrology Dialysis Transplantation 2012, 27:174-181.